Carvykti Reveals Scale-Out Bottlenecks

Legend Bio and Johnson & Johnson's Carvykti (ciltacabtagene autoleucel) is a marketed autologous CAR-T targeting B-cell maturation antigen (BCMA). Q2 2026 revenue increased by 49% year-over-year to USD 657 million, with the supply chain expanded to 348 treatment centers across 19 markets. However, because each patient requires individual leukapheresis, genetic modification, quality testing, and shipping, demand growth requires scale-out—expanding manufacturing lines in parallel—rather than large-batch production. As a result, both clinical efficacy and manufacturing success rate and turnaround time have become key commercial metrics determining revenue growth.

Four Manufacturing Sites Still Can't Eliminate Operational Complexity

Legend operates four sites: the expanded facility in Raritan, New Jersey; Novartis' contract manufacturing site in New Jersey; and Ovilex and Tecrein in Belgium. Raritan's installed manufacturing capacity is up to 10,000 patients annually, with the company reporting a 99% manufacturing success rate, a median U.S. turnaround time of 29 days, and on-time shipments exceeding 95%. These figures demonstrate industrial progress, but the structure remains vulnerable: any misalignment in raw materials, skilled labor, analytical testing, manufacturing slots, or hospital schedules can delay patient treatment. Carvykti's growth requires continuous capital investment in capacity expansion and process automation, making it economically distinct from the scale-up of conventional antibodies.

LB2501 Turns the Patient's Body into a Production Facility

Legend's LB2501 is a Phase 1 candidate that generates CD19·CD20-targeting CAR-T in vivo via a single lentiviral vector administration. In initial data from 12 patients with relapsed/refractory B-cell non-Hodgkin lymphoma, dose-dependent CAR-T expansion was observed, administered without prior lymphodepletion, and as of the data cutoff date, no dose-limiting toxicity, serious adverse events, or deaths were reported. The in vivo approach replaces patient-specific cell batches with standardized vector products, potentially reducing logistics and manufacturing batches. However, as a small initial result from 12 patients, long-term safety, off-target cell transduction, and efficacy compared to existing therapies will depend on follow-up data.

Approval Expansion Boosts Demand and Elevates Manufacturing Innovation Value

The FDA initially approved Carvykti on February 28, 2022. Following an 11-0 vote by the Oncologic Drugs Advisory Committee on March 15, 2024, the indication was expanded on April 5 to include patients with relapsed/refractory lenalidomide-resistant multiple myeloma who have received at least one prior therapy. On June 27, 2025, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) for approved BCMA·CD19 autologous CAR-Ts, including Carvykti, improving access for community and outpatient settings. Global CAR-T annual revenue is projected to exceed USD 7.4 billion in 2026, with multiple myeloma competition including Abecma (idecabtagene vicleucel, BCMA), Tecvayli (teclistamab, BCMA×CD3), and Elrexfio (elranatamab, BCMA×CD3). If in vivo CAR-T reduces manufacturing time and treatment center burden, the competitive axis between products will shift from response rates to immediate availability, outpatient administration feasibility, and total cost of care.